A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

Summary

This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years

Eligibility

Inclusion Criteria:

* measurable metastatic uveal melanoma.
* No concomitant therapy.
* Prior PD1 or tebendafesp allowed.
* Performance status 0-1.
* No active Hepatitis B.
* No known HIV infection.
* WBC\>2000, ANC\>1500, Hgb \>8.
* Creatinine \< 3 x ULN.
* AST \& ALT \< 2.5 x ULN Bilirubin \< 2 x ULN.
* Albumin \>2.9

Exclusion Criteria:

* Liver tumor volume \> 50%.
* Active CNS metastases.
* Pregnancy.
* Prior therapy with Opdualag or relatlimab
* Certain autoimmune diseases.
* Previous liver embolization or radiation.
* Use of systemic steroids

Conditions2

Interventions1

Locations1 site

Find trials near these locations

Related trials

• A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. — David Palma
• AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer — IRCCS San Raffaele
• Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC — Peking University First Hospital
• Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer — The Second Hospital of Shandong University
• Association of Psychological Distress in Patients With Lung Cancer — Shanghai Chest Hospital
• BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases — Shandong Cancer Hospital and Institute
• CIETAI and Sequential Radiotherapy in Squamous Lung Cancer — Dong Wang
• Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Browse More Trials